Longevica Therapeutics has established a scientific advisory board to support development of its longevity platform, which includes a companion-animal programme alongside its human-health research.
The company says its research platform is based on a large in-vivo programme involving more than 16,000 mice and 1,033 small-molecule compounds. Longevica is using the resulting data to identify potential interventions associated with healthy ageing and lifespan.
Companion Animals as a Translational Platform
The company’s strategy places dogs and cats within a broader longevity-development framework.
Companion animals can provide an important translational research population because naturally ageing dogs and cats share environmental exposure and age-related disease characteristics that differ from highly controlled laboratory models.
Strategic Significance
The emergence of veterinary longevity programmes is creating a new intersection between:
geroscience → veterinary medicine → companion-animal therapeutics → human translational research.
The sector remains scientifically early, however, and evidence generated in laboratory animals does not automatically establish clinical efficacy in dogs, cats or humans.
Analyst View
The commercial opportunity in pet longevity could eventually extend across pharmaceuticals, diagnostics, nutrition and monitoring technologies.
The important indicators will be controlled clinical data, validated biomarkers, safety, regulatory pathways and evidence that interventions improve healthspan, rather than simply extending lifespan.
